Marcy Vallone, Senior Vice President, Development Innovations at Sarah Cannon Research Institute, shared a post on LinkedIn:
“Each day, dedicated researchers and staff invest time and energy into the clinical trial process to bring cutting-edge therapies to patients.
At Sarah Cannon Research Institute, we asked ourselves: How can we make that process easier, faster, and more impactful, especially in the communities where most patients with cancer receive care?
The answer: Accelero.
Clinical trials are what make breakthrough therapies possible and our team is transforming how they are delivered in oncology. With an innovative model that supports trial sites, eases biopharma sponsor burdens, and ultimately accelerates patient access to breakthrough treatments, Accelero is helping bring these treatments to the patients who need them most.
Read the full article co-authored with my colleague, Jennifer Cole, Senior Vice President, Research Operations, SCRI.”
Erika Hamilton, Chair, Executive Committee Breast and Breast Program Lead at Sarah Cannon Research Institute, shared this post, adding:
“So excited for these advances to come to fruition under the leadership of Marcy Vallone and Jennifer Cole via Sarah Cannon Research Institute’s Accelero.
We all recognize that clinical trials could and should be easier for stakeholders:
- More streamlined and efficient for patients that need them.
- Less burdensome on research staff handling data and queries.
- Easier for physicians with more inclusive protocols and patient matching.
- Faster in start up with more rapid accrual for pharma.
Accelero aims to improve all of these, streamlining processes so we can all deliver advances for patients faster in oncology.”
More posts from Sarah Cannon Research Institute.